Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $87.14 Average PT from Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $87.1429.

A number of analysts have recently weighed in on ESTA shares. Needham & Company LLC increased their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. BTIG Research increased their price objective on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th.

Insider Buying and Selling at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is owned by company insiders.

Institutional Trading of Establishment Labs

A number of large investors have recently modified their holdings of ESTA. NewEdge Advisors LLC increased its position in Establishment Labs by 14.8% in the 1st quarter. NewEdge Advisors LLC now owns 10,284 shares of the company’s stock valued at $584,000 after acquiring an additional 1,327 shares during the period. Bank of America Corp DE increased its position in Establishment Labs by 56.7% in the 1st quarter. Bank of America Corp DE now owns 416,840 shares of the company’s stock valued at $23,668,000 after acquiring an additional 150,797 shares during the period. ADAR1 Capital Management LLC increased its position in Establishment Labs by 24.5% in the 1st quarter. ADAR1 Capital Management LLC now owns 213,473 shares of the company’s stock valued at $12,121,000 after acquiring an additional 42,051 shares during the period. California State Teachers Retirement System increased its position in Establishment Labs by 42.3% in the 1st quarter. California State Teachers Retirement System now owns 22,120 shares of the company’s stock valued at $1,256,000 after acquiring an additional 6,579 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in Establishment Labs in the 1st quarter valued at approximately $318,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Stock Down 0.2%

Shares of Establishment Labs stock opened at $82.39 on Friday. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The business’s 50 day simple moving average is $70.25 and its 200-day simple moving average is $69.48. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -55.29 and a beta of 1.11. Establishment Labs has a twelve month low of $33.35 and a twelve month high of $86.00.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Equities research analysts forecast that Establishment Labs will post -1.07 earnings per share for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.